Allosteric drugs: thinking outside the active-site box.

[1]  J. Changeux,et al.  Allosteric proteins and cellular control systems. , 1963, Journal of molecular biology.

[2]  C. Yanofsky,et al.  Mutational studies with the trp repressor of Escherichia coli support the helix-turn-helix model of repressor recognition of operator DNA. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[3]  A. Joachimiak,et al.  The crystal structure of trp aporepressor at 1.8 Å shows how binding tryptophan enhances DNA affinity , 1987, Nature.

[4]  O. Halevy,et al.  Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53 , 1990, Cell.

[5]  J. Wells,et al.  Additivity of mutational effects in proteins. , 1990, Biochemistry.

[6]  Mike Carson,et al.  RIBBONS 2.0 , 1991 .

[7]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[8]  A. G. Day,et al.  Step-wise mutation of barnase to binase. A procedure for engineering increased stability of proteins and an experimental analysis of the evolution of protein stability. , 1993, Journal of molecular biology.

[9]  P. Jeffrey,et al.  Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. , 1994, Science.

[10]  D. Lane,et al.  Small peptides activate the latent sequence-specific DNA binding function of p53 , 1995, Cell.

[11]  C. Prives,et al.  Regulation of Mutant p53 Temperature-sensitive DNA Binding* , 1996, The Journal of Biological Chemistry.

[12]  A. Fersht,et al.  Thermodynamic stability of wild-type and mutant p53 core domain. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[13]  B. Groner,et al.  Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain , 1997, Nature Medicine.

[14]  J. Boeke,et al.  Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations , 1998, The EMBO journal.

[15]  Jeffrey A. Lefstin,et al.  Allosteric effects of DNA on transcriptional regulators , 1998, Nature.

[16]  Lewis E. Kay,et al.  Protein dynamics from NMR , 1998, Nature Structural Biology.

[17]  B. Foster,et al.  Pharmacological rescue of mutant p53 conformation and function. , 1999, Science.

[18]  E. Pennisi.  Bracing p53 for the War on Cancer , 1999, Science.

[19]  A. Fersht,et al.  Mechanism of rescue of common p53 cancer mutations by second‐site suppressor mutations , 2000, The EMBO journal.

[20]  A. Fersht,et al.  Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy , 2000, Oncogene.

[21]  N. Sigal,et al.  Allosteric inhibitors of inducible nitric oxide synthase dimerization discovered via combinatorial chemistry. , 2000, Proceedings of the National Academy of Sciences of the United States of America.